COMMUNIQUÉS West-GlobeNewswire

Xenon to Report Q2 2026 Financial Results on August 6, 2026
30/07/2026
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
30/07/2026
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod
30/07/2026
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod La Société confirme être en bonne voie pour déposer, d’ici la fin de l’année 2026, sa première demande d’autorisation [...]
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30/07/2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative [...]
Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
30/07/2026
Financial Highlights† Reported revenue of $418.8 million, up 10% Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively GAAP operating margin of 14.4%, compared to 12.3% in [...]
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
30/07/2026
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the [...]
Stryker reports second quarter 2026 operating results
30/07/2026
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased 9.4% to $6.6 billion Organic net [...]
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
30/07/2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
30/07/2026
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and [...]
GenomOncology Announces Integrated End-to-End Workflow Using PacBio’s Long-Read Whole-Genome Sequencing Technology in Oncology
30/07/2026
Combined sample-to-report solution pairs PacBio HiFi WGS with GenomOncology Pathology Workbench to support clinical labs in delivering configurable, reimbursement-aligned genomic reports across tumor types CLEVELAND, [...]
CooperCompanies Announces Release Date for Third Quarter 2026
30/07/2026
SAN RAMON, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report third quarter 2026 financial results on Wednesday, September 9 [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
30/07/2026
PARIS, 30 juill. 2026 (GLOBE NEWSWIRE) -- Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers Paris, France, le 30 juillet 2026 Place de cotation [...]
Voting Rights and Shares Capital of the Company
30/07/2026
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés [...]
STERIS Raises Dividend to $0.69 per share
30/07/2026
DUBLIN, IRELAND, July 30, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.69 per share. This represents a $ [...]
Cellectis publiera ses résultats financiers du deuxième trimestre jeudi 6 août 2026
30/07/2026
NEW YORK, 30 juill. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des [...]
Cellectis to Report Second Quarter Financial Results on August 6, 2026
30/07/2026
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
30/07/2026
Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT FocalTherics ™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 Company to host conference call and webcast on [...]
Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
30/07/2026
No Stockholder Action Required at This Time REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that [...]
DBV Technologies annonce le placement d’ADS pour un montant d’environ 50 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
30/07/2026
Châtillon, France, 30 juillet 2026 DBV Technologies annonce le placement d’ADS pour un montant d’environ 50 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « [...]

Pages